BRINZOLAMIDE

Post-LOE

brinzolamide

Design Pharmaceuticals

ANDAOPHTHALMICSUSPENSION/DROPS

Approved

Jul 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

BRINZOLAMIDE (brinzolamide) by Design Pharmaceuticals is carbonic anhydrase inhibitors [moa]. Approved for elevated intraocular pressure (iop) in patients with ocular hypertension, open-angle glaucoma, hypertension and 1 more indications. First approved in 2023.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

Carbonic Anhydrase Inhibitors

Pharmacologic Class:

Carbonic Anhydrase Inhibitor

Indications (4)

elevated intraocular pressure (IOP) in patients with ocular hypertension open-angle glaucoma

Worked on BRINZOLAMIDE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT03896633Phase 1/2Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Started Feb 2018

637 enrolled

GlaucomaOpen Angle or Ocular Hypertension

NCT03150160Phase 4Completed

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Started Sep 2017

1 enrolled

Glaucoma

NCT02339584Phase 3Completed

Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Started Apr 2015

493 enrolled

Open-Angle GlaucomaOcular Hypertension

NCT02140060Phase 2Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Started Jun 2014

327 enrolled

GlaucomaOcular Hypertension

NCT01514734Phase 4Terminated

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Started Mar 2012

9 enrolled

Glaucoma